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Animal preparation
The Animal experimentation ethics Committee of the Florey Institute approved the study. Seven merino ewes weighing between 35 and 55 kg were procured for chronic instrumentation. The animals underwent three separate operations prior to experimentation, as previously described 8, 9 .
The first surgical procedure consisted of oophorectomy and carotid loop formation. Two weeks later, we implanted transit-time flow probes (20 mm, respectively) (Transonics Systems, Ithaca, Ny, U.S.A.) around the ascending aorta and, after a further two weeks, we implanted transit-time flow probes (6 mm and 4 mm, respectively) around the superior mesenteric and left renal arteries. The transit-time flow probes on regional blood vessels were connected to flowmeters (Transonics Systems, Ithaca, Ny, U.S.A.) two weeks after surgery.
The day before the experiment, we implanted a carotid loop arterial Tygon catheter (inner diameter, 1.0 mm; outer diameter, 1.7 mm) (Cole-Parmers; Boronia, Australia) and two internal jugular venous polythene catheters (Critchley, Silverwater, Australia) (inner diameter, 1.2 mm; outer diameter, 1.7 mm) for the measurement of arterial and central venous pressures and for fluid infusion. A urinary catheter was inserted for urine sampling and flow measurement. Analog signals (mean arterial pressure, central venous pressure, cardiac output and regional blood flows) were collected using a personal computer data acquisition system with custom software written at the Howard Florey Institute. Data were collected at 100 Hz for 10 seconds at one minute intervals throughout the experiment protocol.
Experimental protocol
Before randomisation, all animals were monitored for 30 minutes (control period) and then randomised by means of random numbers into control group, normal saline group or Gelofusine ® group. each animal received one of the following: observation (control), a bolus of normal saline (one litre over 15 minutes) or a bolus of Gelofusine ® (one litre over 15 minutes). Monitoring was continued for a three-hour period after the start of the infusion.
Urine and blood samples were collected at 0, 15, 30, 60, 90, 120, 150 and 180 minutes. Blood gases and haemoglobin were measured using a Radiometer blood gas machine (ABL system 625/620 Radiometer, Copenhagen, Denmark). Serum and urinary creatinine were measured using an automated multi-channel biochemical analyser (Hitachi 747, Roche Diagnostics, Sydney, N.S.W.). osmolarity was measured using the freezing point technique and is reported in mosm/l. oxygen delivery (Do 2 ) was calculated by following equation:
At the end of the experiment, all catheters were removed and the animals were allowed to recover for five to seven days before being randomly crossed over to another arm of the study.
Statistical analysis
To adjust for the effect of body weight and baseline variability in a relatively small cohort of animals, we compared the relative change (baseline -post-intervention value/baseline value) in the value of all variables for the three different interventions. We present these changes using the baseline as the reference point. Friedman's non-parametric analysis of variance was used to compare the overall change from baseline over time among the three groups. The Wilcoxon-signed rank test was performed to compare the study variables between any of the two different interventions. A P<0.05 was considered statistically significant.
ReSULTS

Systemic haemodynamic effects
Compared to the control group, during the first hour, resuscitation with both fluids induced a greater increase in mean arterial pressure, stroke volume, cardiac output and central venous pressure (P<0.05 for all) ( Figure 1 ). However, the central venous pressure increased more with Gelofusine ® than saline (6.97±3.67 mmHg vs. 3.94±2.31, P<0.05). In addition, Gelofusine ® induced a higher cardiac output throughout the three hours of observation (P<0.05) ( Figure 1 ). This increase was mostly dependent on an increase in heart rate in the last two hours of the experiment compared to control or saline (increase with Gelofusine ® of 12.5 beats/minute compared to baseline vs. -1.7 beats/minute for saline and -1 beat/minute for controls). 
Mesenteric blood flow
During the first hour, normal saline increased mesenteric blood flow significantly more than controls, while Gelofusine ® did not ( Figure 2 ). However, this difference between the two fluids was transient and had dissipated by 120 minutes. Changes in mesenteric conductance with the two fluids were negligible ( Figure 2 ). Renal blood flow Gelofusine ® significantly and progressively increased renal blood flow and renal conductance throughout the study period. After 180 minutes, the mean increase in RBF with Gelofusine ® was markedly greater than with saline (76.56± 47.90 ml/minute vs. 3.77±17.55, ml/minute P <0.05; Figure 3 ). The increase in RBF induced by Gelofusine ® was associated with a significant, parallel and commensurate increase in renal conductance.
Oxygen delivery
Despite the increase in cardiac output, Gelofusine ® and normal saline did not affect systemic and mesenteric oxygen delivery (Figure 4 ), as haemoglobin levels significantly decreased with both fluids during the first hour post-infusion (9.86±1.10 in controls vs. 6.44±0.74 in the Gelofusine ® group and 7.67±0.77 g/dl in the normal saline group, respectively, P <0.05) and remained lower until the second hour.
In contrast, during the first hour, renal oxygen delivery (renal DO 2 ) significantly decreased with both fluids (Figure 4 ) and only recovered at 90 minutes. Renal function Although urine output significantly increased with both fluids in the first hour, only Gelofusine ® achieved a sustained effect ( Figure 5 ).
During the first hour, both fluids similarly and significantly increased creatinine clearance ( Figure 5 ). This effect dissipated in the following two hours.
In the first hour, both fluids reduced urine sodium excretion and urine osmolarity. Gelofusine ® , however, appeared to have a more sustained effect ( Figure 6 ).
DISCUSSIoN
We performed an experimental study to compare the effects on regional blood flow and regional oxygen delivery of 4% succinylated gelatin solution (Gelofusine ® ) with those of normal saline. In this randomised, controlled, cross-over large animal study, we found that fluid resuscitation with normal saline or Gelofusine ® achieved volume expansion effects on systemic haemodynamics and mesenteric blood flow and conductance. However, we also found that Gelofusine ® led to a significantly greater increase in central venous pressure and cardiac output, an increase in both renal blood flow and renal conductance and a greater and more sustained effect on urine output. Both fluids also transiently increased creatinine clearance and achieved a sustained decrease in urinary sodium excretion and urine osmolarity. These effects on renal function occurred while there was a significant fluid-induced decrease in renal oxygen delivery, which lasted more than an hour.
our findings are consistent with previous observations on the effects of saline on regional blood flows and function 12 . They confirm that a saline bolus induces a short-lived increase in central venous pressure and cardiac output and that these changes have transient effects on regional circulations with the exception of the kidney. However, to our knowledge, this is the first controlled evaluation of the systemic and regional effects of Gelofusine ® in a large mammal.
Accordingly, this is the first time that saline and Gelofusine ® have been compared head-on in terms of their systemic and regional effects. Our observations suggest that these two fluids have similar volume expansion effects on the systemic circulation. However, their renal effects differ. In particular Gelofusine ® appears to be associated with a specific renal vasodilatory effect, which induces a sustained and progressive increase in renal blood flow. This increase lasts longer than the transient volume expansion effect on the systemic circulation. In fact, the increase in conductance (vasodilatation) and the increase in renal blood flow continued despite the fact that the volume effects of the fluid on cardiac output, mean arterial pressure, stroke volume and central venous pressure had mostly dissipated. This dissociation between renal blood flow and intravascular volume expansion suggests a specific renal effect of Gelofusine ® . At least three theories can be advanced to explain these observations. One is that the renal vasodilatation seen with Gelofusine ® might be secondary to the effect of an amino acid load on the renal vasculature. Many studies have shown an up to 50% increase in RBF following ingestion of a protein-rich meal or the acute intravenous infusion of amino acids in animals and humans [13] [14] [15] [16] . The gelatin component of Gelofusine ® could easily act as such an amino acid load. When an amino acid load is given, the elevation in RBF is typically dose dependent and associated with a reduction in renal vascular resistance 17, 18 . This is what we observed in our animals. Another possible explanation is that Gelofusine ® administration resulted in the delivery of a significant arginine load (3.2 to 3.6 g in one litre of gelatin) 19, 20 . As arginine is a precursor of nitric oxide [21] [22] [23] [24] and as nitric oxide is a known renal vasodilatory substance [22] [23] [24] [25] [26] , such arginine administration could conceivably have increased renal nitric oxide production and release and consequently induced vasodilatation. However, the lack of vasodilatation in the systemic and mesenteric beds does not support this latter explanation. Unfortunately, we were unable to obtain renal vein blood to confirm or refute increased release of nitric oxide. A third possible explanation relates to the effect of haemodilution per se on vascular resistance 27 . In this regard several studies have shown that the rheological changes induced by haemodilution can account for important decreases in systemic and regional resistance to flow with associated decreases in calculated vascular resistance (increased conductance) 28 . However, this possible explanation is not logically consistent with the data as vasodilatation increased over time in a progressive fashion after Gelofusine ® administration while the degree of haemodilution progressively decreased. Furthermore, when haemodilution was maximal the changes in renal vascular conductance were small. Finally, although saline and Gelofusine ® had a similar effect on haemodilution, their effect on renal vascular conductance was clearly different in timing, pattern and magnitude.
Neither saline nor Gelofusine ® significantly increased systemic or regional oxygen delivery at any time after infusion. In fact, both fluids significantly decreased renal oxygen delivery during the first hour post infusion. This effect appeared mainly due to haemodilution with a 2 to 3 g/dl decrease in haemoglobin concentration. Even after three hours, systemic or regional oxygen delivery with fluids did not appear superior to observation alone. Gelofusine ® appeared to increase the heart rate in the second and third hour after infusion but such increase was dissociated from haemodilution and its mechanism remains unclear. It is worthy of note that the decrease in renal oxygen delivery occurred despite an increase in urine output and creatinine clearance showing a degree of dissociation between typical clinical measures of renal function and renal oxygen delivery.
Finally, we observed a significant and sustained decrease in urine sodium concentration and urine osmolarity with both fluids. These observations are consistent with decreased ADH activity induced by volume expansion 29,30 .
Our study has both strengths and limitations. The possible strengths include the presence of a control group, the use of an equivalent dose of sodium chloride, the study of conscious animals free from the effects of anaesthesia or sedation on regional blood flow, the assessment of renal function and the measurement of study variables over an extended period. An important limitation of our study, however, relates to its assessment of regional flows without simultaneous measurement of regional oxygen extraction. This makes it difficult to assess the consequences of changes in oxygen delivery. However, we wished to study conscious animals. We have found that this approach makes it technically extraordinarily difficult to maintain cannulation of regional veins. This technical limitation also made it impossible to measure markers of nitric oxide release in renal vein blood. We did not induce haemorrhagic shock prior to fluid administration, making our observations less clinically relevant to one setting in which such fluids might be given. However, we consider that the first fundamental step in understanding the effect of the study fluids on regional beds would be to assess them in the normal mammalian circulation. The observation that in normal animals the findings for normal saline mirror those reported in hyperdynamic sepsis 12 , supports the relevance of such an initial approach. We now intend to study these fluids further in a variety of disease states, as the relevance of these findings to critically ill humans remains unclear. We used Gelofusine ® as a representative of the colloid class instead of 4% human albumin or starch. This is because our first two sheep died of anaphylaxis after receiving human albumin and starch solutions were not available in Australia. We administered the same amount (one litre) of both fluids. As these fluids are not equipotent in terms of volume expansion, differentiating the effects of volume expansion from those specific to a given fluid is difficult. However, there is no information to allow calculation of an equipotent dose of Gelofusine ® and the renal effects of Gelofusine ® demonstrated in this study are clearly unique, delayed in time course, essentially separate from the effects on global haemodynamics and related to renal vascular vasodilatation.
In summary, both normal saline and Gelofusine ® significantly but transiently increase mean arterial pressure, cardiac output, stroke volume, central venous pressure and mesenteric flow. However, Gelofusine ® appears associated with a specific effect to increase renal blood flow, which is mediated by progressive renal vasodilatation. Both fluids similarly increase urine output and creatinine clearance but simultaneously decreased renal oxygen delivery. Knowledge of the nature, magnitude and duration of these changes, as provided by our study may assist clinicians in appreciating how their choice of type and amount of fluid may lead to different physiological consequences.
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